Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares Purchased by Stifel Financial Corp

Stifel Financial Corp boosted its position in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) by 10.4% in the 4th quarter, HoldingsChannel reports. The firm owned 166,000 shares of the company’s stock after purchasing an additional 15,676 shares during the period. Stifel Financial Corp’s holdings in Black Diamond Therapeutics were worth $355,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its stake in Black Diamond Therapeutics by 1.5% in the 4th quarter. Geode Capital Management LLC now owns 959,316 shares of the company’s stock valued at $2,053,000 after purchasing an additional 14,439 shares during the last quarter. Renaissance Technologies LLC raised its stake in Black Diamond Therapeutics by 256.2% in the 4th quarter. Renaissance Technologies LLC now owns 904,000 shares of the company’s stock valued at $1,935,000 after purchasing an additional 650,200 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Black Diamond Therapeutics by 158.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 661,436 shares of the company’s stock valued at $1,416,000 after purchasing an additional 405,579 shares during the last quarter. Affinity Asset Advisors LLC acquired a new position in Black Diamond Therapeutics in the 4th quarter valued at about $1,197,000. Finally, Wellington Management Group LLP raised its stake in Black Diamond Therapeutics by 7.9% in the 4th quarter. Wellington Management Group LLP now owns 221,236 shares of the company’s stock valued at $473,000 after purchasing an additional 16,279 shares during the last quarter. Institutional investors and hedge funds own 95.47% of the company’s stock.

Insider Activity

In related news, major shareholder Growth N. V. Biotech sold 5,784,292 shares of the firm’s stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $2.07, for a total transaction of $11,973,484.44. Following the completion of the transaction, the insider now owns 2,733,547 shares of the company’s stock, valued at $5,658,442.29. This trade represents a 67.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 8.87% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on BDTX. HC Wainwright upped their price objective on shares of Black Diamond Therapeutics from $11.00 to $12.00 and gave the company a “buy” rating in a research note on Tuesday, March 18th. Stifel Nicolaus dropped their price objective on shares of Black Diamond Therapeutics from $16.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, March 7th. Finally, Wedbush reaffirmed an “outperform” rating and set a $11.00 price objective on shares of Black Diamond Therapeutics in a research note on Wednesday, March 19th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $14.60.

Black Diamond Therapeutics Price Performance

Shares of BDTX opened at $1.93 on Wednesday. The business’s fifty day moving average price is $1.59 and its 200 day moving average price is $2.14. Black Diamond Therapeutics, Inc. has a 12-month low of $1.20 and a 12-month high of $6.75. The stock has a market capitalization of $109.39 million, a PE ratio of -1.45 and a beta of 2.63.

Black Diamond Therapeutics (NASDAQ:BDTX) last issued its earnings results on Thursday, March 6th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.03. As a group, research analysts anticipate that Black Diamond Therapeutics, Inc. will post -1.3 earnings per share for the current fiscal year.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.